Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614 |
Resumo: | Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight guideline wording that may allow for multiple interpretations (alternatives to monotherapy with metformin, hierarchy of drugs to be associated with metformin, and metformin contraindications). Furthermore, we argue that it seems that choosing a glycemic target of 6.5% in a normative document to be applied in the general population may have unforeseen consequences. |
id |
RCAP_7053c164cc79ffc7def5a843cb97c9c8 |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/1614 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective.Norma terapêutica da diabetes mellitus tipo 2: metformina uma perspectiva crítica.Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight guideline wording that may allow for multiple interpretations (alternatives to monotherapy with metformin, hierarchy of drugs to be associated with metformin, and metformin contraindications). Furthermore, we argue that it seems that choosing a glycemic target of 6.5% in a normative document to be applied in the general population may have unforeseen consequences.Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight guideline wording that may allow for multiple interpretations (alternatives to monotherapy with metformin, hierarchy of drugs to be associated with metformin, and metformin contraindications). Furthermore, we argue that it seems that choosing a glycemic target of 6.5% in a normative document to be applied in the general population may have unforeseen consequences.Ordem dos Médicos2011-04-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614oai:ojs.www.actamedicaportuguesa.com:article/1614Acta Médica Portuguesa; Vol. 24 No. 2 (2011): Março-Abril; 331-8Acta Médica Portuguesa; Vol. 24 N.º 2 (2011): Março-Abril; 331-81646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614/1196Pinto, DanielHeleno, BrunoGallego, RosaSantos, IsabelSantiago, Luiz MiguelMaria, Vascoinfo:eu-repo/semantics/openAccess2022-12-20T10:58:16Zoai:ojs.www.actamedicaportuguesa.com:article/1614Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:16.459639Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective. Norma terapêutica da diabetes mellitus tipo 2: metformina uma perspectiva crítica. |
title |
Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective. |
spellingShingle |
Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective. Pinto, Daniel |
title_short |
Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective. |
title_full |
Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective. |
title_fullStr |
Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective. |
title_full_unstemmed |
Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective. |
title_sort |
Guideline: type 2 diabetes mellitus therapy: metformin, a critical perspective. |
author |
Pinto, Daniel |
author_facet |
Pinto, Daniel Heleno, Bruno Gallego, Rosa Santos, Isabel Santiago, Luiz Miguel Maria, Vasco |
author_role |
author |
author2 |
Heleno, Bruno Gallego, Rosa Santos, Isabel Santiago, Luiz Miguel Maria, Vasco |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Pinto, Daniel Heleno, Bruno Gallego, Rosa Santos, Isabel Santiago, Luiz Miguel Maria, Vasco |
description |
Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight guideline wording that may allow for multiple interpretations (alternatives to monotherapy with metformin, hierarchy of drugs to be associated with metformin, and metformin contraindications). Furthermore, we argue that it seems that choosing a glycemic target of 6.5% in a normative document to be applied in the general population may have unforeseen consequences. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-04-30 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614 oai:ojs.www.actamedicaportuguesa.com:article/1614 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/1614 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/1614/1196 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 24 No. 2 (2011): Março-Abril; 331-8 Acta Médica Portuguesa; Vol. 24 N.º 2 (2011): Março-Abril; 331-8 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130626075394048 |